Millennium Management’s Structure Therapeutics GPCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.14M Buy
168,931
+16,371
+11% +$1.12M ﹤0.01% 2379
2025
Q4
$10.6M Sell
152,560
-1,121,991
-88% -$45.8M ﹤0.01% 2204
2025
Q3
$35.7M Buy
1,274,551
+54,496
+4% +$1.09M 0.02% 1112
2025
Q2
$25.3M Buy
1,220,055
+429,896
+54% +$9.45M 0.01% 1356
2025
Q1
$13.7M Buy
790,159
+39,146
+5% +$959K 0.01% 1880
2024
Q4
$20.4M Sell
751,013
-160,438
-18% -$5.69M 0.01% 1500
2024
Q3
$40M Sell
911,451
-227,841
-20% -$8.81M 0.02% 977
2024
Q2
$44.7M Buy
1,139,292
+1,048,350
+1,153% +$43M 0.02% 876
2024
Q1
$3.9M Buy
90,942
+74,173
+442% +$3.13M ﹤0.01% 3123
2023
Q4
$684K Sell
16,769
-283,105
-94% -$16.2M ﹤0.01% 4443
2023
Q3
$15.1M Buy
299,874
+255,648
+578% +$8.24M 0.01% 1671
2023
Q2
$1.84M Buy
44,226
+8,767
+25% +$246K ﹤0.01% 3559
2023
Q1
$844K Buy
+35,459
New +$833K ﹤0.01% 4247

Other funds holding GPCR

Millennium Management's GPCR Position: Q1 2026 in Review

Millennium Management increased its Structure Therapeutics (GPCR) stake by 11% in Q1 2026, buying an estimated $1.12M and bringing the position to 168,931 shares worth $8.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2379.

Millennium Management first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $44.7M in Q2 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Millennium Management held 168,931 shares of Structure Therapeutics worth $8.14M as of Q1 2026.
  • Millennium Management bought 16,371 Structure Therapeutics shares in Q1 2026, an estimated $1.12M.
  • Structure Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2379 holding.
  • Millennium Management first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Millennium Management's Structure Therapeutics position peaked at $44.7M in Q2 2024.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.